Quest Diagnostics Likely To Report Higher Q4 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Portfolio Pulse from Avi Kapoor
Quest Diagnostics (NYSE:DGX) is anticipated to report higher Q4 earnings at $2.11 per share compared to $1.98 a year ago, with projected revenue of $2.25 billion versus $2.33 billion previously. The company has also partnered with Fitbit for metabolic health research. Despite this, shares dropped 0.3% to $128.43. Analysts from Truist Securities, B of A Securities, Citigroup, UBS, and JP Morgan have provided various ratings and price targets for DGX, with accuracy rates ranging from 68% to 76%.
February 01, 2024 | 6:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quest Diagnostics is expected to report higher Q4 earnings and has partnered with Fitbit. Analysts have updated their ratings and price targets, indicating a positive outlook despite a recent slight decline in share price.
The expected increase in Q4 earnings and the collaboration with Fitbit suggest a positive outlook for Quest Diagnostics, which could lead to a short-term increase in stock price. However, the recent slight decline in share price indicates market uncertainty, which is countered by positive analyst ratings and raised price targets.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100